Inhibrx Inc - ESG Rating & Company Profile powered by AI
This Sustainability rating for Inhibrx Inc represents the company's transparency towards the UN Sustainable Development Goals. This webpage is a zero-cost ESG analysis covering Inhibrx Inc. This dashboard includes a Q&A section on Inhibrx Inc.
Inhibrx Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 0.0 and governance score of 4.8.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Inhibrx Inc | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Inhibrx Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Inhibrx Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Inhibrx Inc report the average age of the workforce?
Sign up for free to unlockDoes Inhibrx Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Inhibrx Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Inhibrx Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Inhibrx Inc offer flexible work?
Sign up for free to unlockDoes Inhibrx Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Inhibrx Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Inhibrx Inc conduct supply chain audits?
Sign up for free to unlockDoes Inhibrx Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Inhibrx Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Inhibrx Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Inhibrx Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Inhibrx Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Inhibrx Inc disclose water use targets?
Sign up for free to unlockDoes Inhibrx Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Inhibrx Inc have a product recall in the last two years?
Sign up for free to unlockDoes Inhibrx Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Inhibrx Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Inhibrx Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Inhibrx Inc disclose parental leave metrics?
Sign up for free to unlockDoes Inhibrx Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Inhibrx Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Inhibrx Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Inhibrx Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Inhibrx Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Inhibrx Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Inhibrx Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Inhibrx Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Inhibrx Inc disclose its waste policy?
Sign up for free to unlockDoes Inhibrx Inc report according to TCFD requirements?
Sign up for free to unlockDoes Inhibrx Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Inhibrx Inc disclose energy use targets?
Sign up for free to unlockDoes Inhibrx Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Inhibrx Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Inhibrx Inc
These potential risks are based on the size, segment and geographies of the company.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.